Drug
Gastric Inhibitory Polypeptide clinical trials
Also written GIP.
- studies test it
- 19
- open now
- 6
- in phase 3
- 0
- first study started
- 2003
Keep track of what changes. Save the Gastric Inhibitory Polypeptide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
- GIP
- 8
Studies by the year they started
19 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 2
- No phase
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 18
University Hospital, Gentofte, Copenhagen (3) · Washington University School of Medicine (3) · Asger Lund, MD (2) · Steno Diabetes Center Copenhagen (2) · Rigshospitalet, Denmark (2) · David D'Alessio, M.D. (1) · University of Nottingham (1) · National Institute on Aging (NIA) (1)
Often tested with
Tested in the same studies.
Glucagon-Like Peptide 1 (7) · Xenin 25 (3) · Alanine (2) · Atropine (2) · Semaglutide (1) · Incretins (1) · Glimepiride (1) · Insulin, Regular, Human (1)
Studies
Open first, then newest update. How each study uses Gastric Inhibitory Polypeptide is read from its arms, and is right about nine times in ten.
Testing it · 19
- A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseRecruitingPhase 1Novo Nordisk A/SNCT07411560Written as Glucose-dependent Insulinotropic Polypeptide (GIP)
- Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 InfusionRecruitingNot applicableRigshospitalet, DenmarkNCT07398300Written as GIP
- Beta-cell Response to Incretin Hormones in Cystic FibrosisRecruitingNot applicableUniversity of PennsylvaniaNCT01851694Written as GIP
- Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass SurgeryRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT00992901Written as GLP-1 and GIP
- The Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy IndividualsRecruitingPhase 1University Hospital, Gentofte, CopenhagenNCT06419686Written as GIP
- Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 AnalogueRecruitingPhase 1/2Dr Adnan AghaNCT05751720Written as GIP/GLP-1a
- The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 DiabetesCompletedNot applicableAsger Lund, MDNCT06881472Written as Glucose-dependent Insulinotropic Polypeptide (GIP)
- The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 DiabetesCompletedNot applicableAsger Lund, MDNCT05078255Written as Glucose-dependent insulinotropic polypeptide (GIP)
- Incretin Action in Physiology and DiabetesCompletedPhase 1David D'Alessio, M.D.NCT02550548Written as GIP infusion
- Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 DiabetesCompletedNot applicableSteno Diabetes Center CopenhagenNCT03556098Written as glucose-dependent insulinotropic peptide
- The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 DiabetesCompletedNot applicableSteno Diabetes Center CopenhagenNCT03734718Written as GIP
- The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without SulphonylureaCompletedNot applicableUniversity Hospital, Gentofte, CopenhagenNCT03081676Written as Glucose-Dependent Insulinotropic Polypeptide
- The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin SecretionCompletedPhase 1Washington University School of MedicineNCT01951729Written as GIP with atropine
- Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes MellitusCompletedPhase 1Washington University School of MedicineNCT00798915Written as Glucose-dependent Insulinotropic Polypeptide (GIP)
- Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal MuscleCompletedNot applicableUniversity of NottinghamNCT02370745Written as GIP
- Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?CompletedPhase 1/2University Hospital, Gentofte, CopenhagenNCT01048268Written as glucose-dependent insulinotropic polypeptide
- Hyperglycemia and the Extra-pancreatic Effect of IncretinsCompletedNot applicableRigshospitalet, DenmarkNCT01749163Written as GIP
- Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell FunctionCompletedPhase 1Washington University School of MedicineNCT00949663Written as Glucose-dependent Insulinotropic Polypeptide (GIP)
- GIP: Glucose-dependent Insulinotropic PeptideCompletedPhase 1National Institute on Aging (NIA)NCT00239707Written as GIP
Codes
What other systems call Gastric Inhibitory Polypeptide · ClinicalTrials.gg INT007544
- MeSH (NLM) D005749Gastric Inhibitory PolypeptideOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D005749 | Gastric Inhibitory Polypeptide | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.